Australian people can buy antibiotics in Australia online here: http://buyantibioticsaustralia.com/ No prescription required and cheap price!

Microsoft word - north shore cancer research association study list

North Shore Cancer Research Association Study List
Edward Kaplan, MD
9631 Gross Point Rd. Suite 10
847.675.3900 (phone)
Marlon Kleinman, MD
Skokie, IL 60076
847.675.3930 (fax)
Sponsor Protocol # Study Title
A Phase II Study of Systemic High-Dose Methotrexate for the Treatment of Glioblastoma Multiforme in Newly Diagnosed A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND# 60, 265) versus Radiation Therapy and BCNU for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Adjuvant
Sponsor Protocol # Study Title
Cyclophosphamide and Doxorubicin (CA) (4 vs 6 cycles) Versus Paclitaxel (12 weeks vs 18 weeks) as Adjuvant Therapy for Women with Node-Negative Breast Cancer A 2x2 Factorial Phase A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil or Doxorubicin and Cyclophosphamide vs. Capecitabine in Women 65 yrs & Older with Node Positive or High-Risk Node Negative A Clinical Trial Comparing Anastrozole or Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy Wednesday, October 26, 2005
Page 1 of 10
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast METASTATIC
Sponsor Protocol # Study Title
A Phase II Trial of Capecitabine in Combination with the Farnesyltransferase Inhibitor, R115777 (Tipifarnib, Zarnestra) in A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone (BMS-247550) and Carboplatin in Patients with HER2/Neu- An Open-label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) In Patients with Locally Advanced 3066A1-303-WW Phase 3 Randomized, Placebo-controlled, Double-Blind Study of Oral CCI-779 Administered in Combination with Letrozole versus Letrozole alone as First Line Hormonal Therapy in Postmenopausal Women Locally Advanced or Metastatic Breast Gastrointestinal
Colon/Rectal
Sponsor Protocol #
Study Title
PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. Every Two Weeks with Bevacizumab to the same Regimen without Bevacizumab for thetreatment of Patients with Resected Stages 2 & 3 Carcinoma of Wednesday, October 26, 2005
Page 2 of 10
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Sponsor Protocol #
Study Title
A Phase III Trial of Adjuvant Chemoradiation after Resection of Gastric and Gastroesophageal Adenocarcinoma Sponsor Protocol #
Study Title
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Pancreatic
Sponsor Protocol #
Study Title
A Randomized Phase III Trial of Gemcitabine Plus Bevacizumab (NSC#704865 IND#7921) versus Gemcitabine Plus Placebo in Patients with Advanced Pancreatic Cancer A Phase 2 Trial of Irinotecan/Docetaxel for Adv. Pancreatic Cancer,with Randomization between Irinotecan/Docetaxel & Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor This study is suspended to A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy versus Gemcitabine Alone in Patients with Localized, Unresectable Pancreatic Cancer A Randomized Phase 3 Study of the Efficacy and Safety of Glufofsamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine Wednesday, October 26, 2005
Page 3 of 10
Genitourinary
Prostate
Sponsor Protocol #
Study Title
Intermittent Androgen Deprivation in Patients with Stage D2 Study of Epoetin Alfa vs Epoetin Alfa with Dexamethasone in Hormone Refractory Prostate Cancer Patients: Impact on Fatigue, Anemia, Functional Status and Quality of Life Phase 3 Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients with Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen Sponsor Protocol #
Study Title
A Phase 2 Trial Evaluating Atrasentan in Patients with Advanced Renal Cell Cancer Note: Currently, this study is open only to patients with non-measurable disease with bone metastases who Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features Phase II Trial of Paclitaxel Plus Carboplatin in Patients with Metastatic or Locally Advanced Collecting Duct Renal Cell Head & Neck
Advanced
Wednesday, October 26, 2005
Page 4 of 10
Protocol #
Study Title
Phase II of PS-341 (NSC 681239) Followed by the Addition of Suspended
Doxorubicin at Progression in Advanced Adenoid Cystic Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Leukemia
Sponsor Protocol #
Study Title
Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission. Please offer ECOG 3903 to patients who consent to Sponsor Protocol #
Study Title
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy prior to Autologous Stem Cell Transplantation Please offer ECOG 3903 to patients who A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Phase II Studies of Two Different Schedules and Two Different Doses of The Farnesyl Transferase Inhibitor R 115777 (Tipifarnib, Zarnestra, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) In Patients of Age 70 or Older Wednesday, October 26, 2005
Page 5 of 10
CLL
Sponsor
Protocol #
Study Title
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Sponsor Protocol #
Study Title
A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase LABORATORY
Sponsor Protocol #
Study Title
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia Miscellaneous
Sponsor Protocol #
Study Title
A Phase II Study of Initial Treatment with Methotrexate in Large Non-Small Cell
Sponsor Protocol #
Study Title
A Randomized Multicenter Phase II Study of Taxane/Carbo/Cetuximab versus Taxane/Carbo as First-Line treatment for Patients with Advanced/Metastatic Non-Small Cell A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy With or Without Thalidomide, in Patients with Wednesday, October 26, 2005
Page 6 of 10
A Double Blind Phase II Study of BAY-43-9006 in Patients with Suspended
Non-Small Cell Lung Cancer who have Failed at Least Two A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the BETA: Phase III / Double-Blind / Placebo-Controlled Trial of Bevacizumab in Combination with Tarceva Compared with Tarceva Alone rfor Treatment of Advanced Non-Small Cell Lung Cancer After Failure of Standard First Line Chemo Molecular Profiling of Non-Small cell Lung Cancer with Clinical Phase I/II Study of Gemcitabine, Carboplatin and Concurrent Suspended
Radiation Therapy in Stage III Non-Small Cell Lung Cancer Sponsor Protocol #
Study Title
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer Small Cell
Sponsor Protocol #
Study Title
Interferon Alpha (NSC#377 523) Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Wednesday, October 26, 2005
Page 7 of 10
Protocol #
Study Title
Phase II Study of Carboplatin plus Paclitaxel Treatment of Lymphoma
Hodgkin's
Sponsor Protocol #
Study Title
A Randomized Phase III Trial of ABVD Versus Stanford V + Radiation Therapy in Locally Extensive and Advanced Stage of Non-Hodgkin's
Sponsor Protocol #
Study Title
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients with Indolent A Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Early High Dose Chemoradiotherapy and ASCT to Conventional Dose CHOP Chemotherapy (with possible Late ASCT) for A Phase II Trial of R-CHOP Followed By Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Wednesday, October 26, 2005
Page 8 of 10
Melanoma
High Risk
Protocol #
Study Title
Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients Randomized Study of Four Weeks High Dose Interferon Alpha-2b Yeast Derived GM-CSF Versus Peptide Vaccination Vs. GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma Metastatic
Sponsor Protocol #
Study Title
A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T cells and Helper T cells for Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Miscellaneous
Sponsor Protocol #
Study Title
ECOG Laboratory Study: Mapping Interactive Cancer Wednesday, October 26, 2005
Page 9 of 10
Anemia
Sponsor
Protocol #
Study Title
FLEXIBILITY: Impact of Once per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects with Non-Myeloid Malignancies with Anemia due to Chemo Catheter Occlusion
Sponsor Protocol #
Study Title
SONOMA 2: Double-Bline, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Multiple Myeloma
Sponsor Protocol #
Study Title
A Randomized Phase III Study of CC-5013 plus Dexamethasone Suspended
versus CC-5013 plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide plus Dexamethasone Salvage Sponsor Protocol #
Study Title
A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary GastroIntestinal Stromal Tumor (GIST) (ECOG A Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec) for Primary and Recurrent Operable Malignant GIST Expressing the Wednesday, October 26, 2005
Page 10 of 10

Source: http://www.nsoncology.com/images/forms/studylist.pdf

alflash.com.ua

The tire pressure warning system is designed to provide warning when tire inflation pressure is critically low while the vehicle is moving. The low tire pressure warning light comes on to inform you that such low tire This system is not designed to operate when the vehicle is stopped. Therefore, check the tire inflation pressure regularly. The recommended cold tire inflation pressure, tire si

Evolution of structure and behaviour of components in mobile architecture

Faculty of Information Technology, Brno University of Technology,Abstract. This paper deals with formal description of structure andbehaviour of component based systems with particular features such asdynamic reconfiguration and component mobility. Those features allowsparts of the component based systems to change their structure andbehaviour at run-time. It can be done by means of creating new

Copyright © 2010-2014 Find Medical Article